← Russell 3000 cross-section

HAE HAEMONETICS CORP

Trailing twelve months to 2026-06-27 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$4.8bn
Revenue TTM
$1.4bn
Net income TTM
$96m
Free cash flow
$291m
Composite score
47.5
Sector rank
#1112

Valuation

P / E
49.8
EV / EBITDA
21.2
EV / sales
4.2
FCF yield
6.08%
Earnings yield vs 10-yr
-2.72pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
7.1%
EBITDA margin
20.0%
ROE
11.5%
ROIC
9.0%
Revenue growth
0.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

During the second quarter of fiscal 2027, we repaid an additional $50.0 million on the revolving credit facility. Financial Summary Net revenues increased 5.6% during the three months ended June 27, 2026 as compared with the same period of fiscal 2026. This was primarily attributable to revenue increases in Apheresis, driven by volume growth and share gains within the Plasma franchise, and revenue increases in MedSurg, driven by share gains in the Hemostasis Management and Transfusion Management product lines within the Blood Management Technologies franchise. Operating income increased 6.7% during the three months ended June 27, 2026 as compared with the same period of fiscal 2026. …HAEMONETICS CORP, 10-Q, period ended 2026-06-27, filed 2026-08-06

Read the full passage →